Back to News
Market Impact: 0.3
Optimi Health To Initiate Phase 2 Psilocybin Trial For Major Depression
Source: Nasdaq
Healthcare & BiotechProduct Launches
Optimi Health plans to initiate a multisite Phase 2 trial of psilocybin-assisted therapy for major depressive disorder. The clinical program advances the commercial-stage psychedelic drug manufacturer's pipeline, though efficacy, safety and regulatory outcomes remain unproven.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
OPTH0.55
More News
- Biotech stocks are surging. How investors can play the new drug innovation boom
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- J&J prostate cancer drug shows promising tumor responses in early trial
- Pfizer reports phase 2 data for 25-valent pneumococcal vaccine
- Fact vs. fiction: Doctors share whether peptides are safe and effective
- Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer